Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer

Table 2

Meta-analysis results of adverse reactions between patients in blank group and observation group.

Adverse reactions	Number of studies	Sample size ()	OR	95% cl
Nausea or vomit	16	911	0.85	[0.61,1.16]	0.30
Hypertension	II	565	6.19	[1.91, 20.20]	0.003
Diarrhea	15	823	0.93	[0.62, 1.40]	0.72
Hand-foot syndrome	14	798	1.35	[0.92, 1.98]	0.13
Proteinuria	II	735	3.97	[1.08, 14.59]	0.03
Myelosuppression	15	878	1.08	[0.72, 1.61]	0.72
Liver damage	4	338	0.87	[0.31, 2.47]	0.79
Mucositis	6	246	1.29	[0.69, 2.44]	0.42
Weakness	13	701	1.08	[0.75,1.54]	0.69
Neuron toxication	6	396	1.15	[0.72, 1.84]	0.55
Haemorrhagia	3	276	1.52	[0.61, 3.76]	0.37
Rash	2	230	1.75	[0.52, 5.90]	0.37